New Zealand markets closed

Heron Therapeutics, Inc. (HRTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
8.38-0.15 (-1.76%)
At close: 04:00PM EST
8.25 -0.13 (-1.55%)
After hours: 07:31PM EST
Full screen
Trade prices are not sourced from all markets
Previous close8.53
Bid8.25 x 3000
Ask8.52 x 3200
Day's range8.27 - 8.83
52-week range8.05 - 20.45
Avg. volume2,082,761
Market cap854.215M
Beta (5Y monthly)1.34
PE ratio (TTM)N/A
EPS (TTM)-2.38
Earnings date22 Feb 2022 - 28 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est31.50
  • Motley Fool

    Why Heron Therapeutics Shares Rose Nearly 15% This Week

    The company announced on Thursday that its drug Zynrelef (bupivacaine and meloxicam) has been given Food and Drug Administration supplemental New Drug Application approval for more uses. The drug, the first FDA-approved dual-acting anesthetic, had already been approved in May for post-surgical pain relief after the removal of bunions, open inguinal hernia operations, or total knee replacement in adults. It has shown to be more effective than just bupivacaine alone, the current standard of care for post-surgical pain, and it gives surgeons a non-opioid solution for post-surgical pain, reducing the possibility of addiction.

  • Motley Fool

    2 Short-Squeeze Candidates That Could Go Parabolic Soon

    Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called "meme stocks" generated jaw-dropping gains for investors earlier this year due to this phenomenon. The mechanics of a short squeeze are fairly straightforward.

  • Zacks

    Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

    Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 15.00% and -7.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?